Navigation Links
Bedford Laboratories(TM) Announces the Acquisition of CAFCIT(R) (Caffeine Citrate) Injection CAFCIT(R) (Caffeine Citrate) Oral Solution
Date:1/3/2008

BEDFORD, Ohio, Jan. 3 /PRNewswire/ -- Bedford Laboratories(TM), a division of Ben Venue Laboratories Inc., announced the acquisition of CAFCIT(R) (caffeine citrate) Injection and CAFCIT(R) (caffeine citrate) Oral Solution from Mead Johnson & Company. Bedford Laboratories is now the reference listed drug holder. CAFCIT(R) (caffeine citrate) is indicated for the short term treatment of apnea in premature infants between 28 and <33 weeks gestational age.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070809/CLTH157LOGO )

"The acquisition of CAFCIT(R) demonstrates our continued commitment to build the most comprehensive and cost effective line of injectable products in the pharmaceutical industry. We are proud to offer a branded product at a generic price," said David Gaugh, Vice President and General Manager of Bedford Laboratories.

Bedford Laboratories will supply latex free CAFCIT(R) (caffeine citrate) Injection and CAFCIT(R) (caffeine citrate) Oral Solution as a sterile liquid in the following presentations:

-- Injection: 60 mg/3 mL single-use vials individually boxed

-- Oral Solution: 60 mg/3 mL single-use vials, 10 vials per child-

resistant container

Prescribing information is available upon request from the Bedford Laboratories' professional services department, (800) 521-5169, or from the company's web site, http://www.bedfordlabs.com.

About Bedford Laboratories

Bedford Laboratories supplies the US and international markets with multisource and specialty injectable products. Headquartered in Bedford, Ohio, Bedford Laboratories is a division of Ben Venue Laboratories, Inc., a subsidiary of Boehringer Ingelheim Corporation located in Ridgefield, CT, and is a part of the Boehringer Ingelheim group of companies.

About Boehringer Ingelheim

Boehringer Ingelheim Corporation based in Ridgefield, CT, is the US headquarters to seven subsidiaries and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 137 affiliates in 47 countries and approximately 38,400 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2006, Boehringer Ingelheim posted net sales of US $13.3 billion (10.6 billion euro) while spending approximately one-fifth of net sales in its largest business, segment Prescription Medicines, on research and development.

For more information, please visit. http://us.boehringer-ingelheim.com .


'/>"/>
SOURCE Bedford Laboratories
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Alma Lasers Announces Proposed Initial Public Offering
2. Smart Balance Announces Conversion of Convertible Preferred Stock
3. IDM Pharma Announces Termination of UVIDEM Development Collaboration and Expected Restructuring in Connection With Evaluation of Strategic Alternatives
4. MQ Associates, Inc. Announces Cash Tender Offer for 121/4% Senior Discount Notes Due 2012 (CUSIP No. 55345RAC2) and Related Consent Solicitation
5. Heska Announces Amended Agreement With AgriLabs
6. Versus Technology Announces Fourth Quarter Results
7. FASgen Announces New Research Discoveries in Lung Cancer
8. Boston Scientific Announces CE Mark Approval for Next-Generation Cardiac Resynchronization Therapy Defibrillator
9. KV Pharmaceutical Company Announces NYSE Listing Extension
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Zyrtec Allergy Tablets(R) and Zyrtec Hives Relief Tablets(R)
11. Transition Therapeutics Announces Appointment of Vice-President of Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... ... 17, 2017 , ... CONTACT:, Glenn Vallecillos, MD, FACS, +1 ... Dr. Glenn Vallecillos experiments SculpSure, the hot, new, aesthetic, non-surgical procedure ... been centered around that idea that to achieve ones desired results a surgical ...
(Date:2/17/2017)... ... 17, 2017 , ... Smiles by Seese is a comprehensive family dental ... Seese leads the practice as a skilled and highly credentialed dentist who is qualified ... serves patients of all ages with excellence in general, restorative, and cosmetic dentistry ...
(Date:2/17/2017)... ... 17, 2017 , ... For the first time, International Scholarship ... exhibit floor for the 2017 HIMSS Conference & Exhibition at the ... more than 40,000 healthcare industry professionals are expected at the conference, where they ...
(Date:2/17/2017)... ... February 17, 2017 , ... Qualis Health, one ... in the 8th Annual DecisionHealth Platinum Awards in recognition of its innovative healthcare ... is recognized across multiple award categories, highlighting four of the organization’s current programs:, ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... executives and focusing on all facets of clinical trial planning and management. Pharmica ... patient engagement, and more. In addition, attendees stopping by Pharmica’s booth were able ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... NEW YORK , Feb. 17, 2017 /PRNewswire/ ... announced today the partnership of their 3D body ... in healthcare IT.  The new integration will be ... on an interactive model of the human body. ... data saves clinicians time, while also increasing the ...
(Date:2/16/2017)... , Feb. 16, 2017 Absorption Systems, ... and medical devices, is pleased to announce that its ... been selected as a winner of the 2017 Executive ... Magazine and recognizes driven executives for their creative ... ethic. The awards ceremony and celebration is on March ...
(Date:2/16/2017)... (NYSE: DVA ) today announced results for the ... Net income attributable to DaVita Inc. for the quarter and ... per share and $880 million, or $4.29 per share, respectively. ... for the quarter and year ended December 31, 2016, excluding ... per share, and $789 million, or $3.85 per share, respectively. ...
Breaking Medicine Technology: